41,200 Shares in Progyny, Inc. $PGNY Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• Virginia Retirement Systems acquired 41,200 Progyny shares worth approximately $1.19 million, while other institutional investors also increased their positions. Institutions and hedge funds collectively own 94.93% of PGNY.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $34.36, above the reported share price of $27.35.
• Progyny exceeded quarterly earnings expectations, reporting $0.55 in EPS versus $0.33 expected and $350.51 million in revenue. The company also authorized a $200 million share-repurchase program covering up to 10.3% of outstanding shares.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 41,200 shares of the company's stock, valued at approximately $1,188,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.05% of Progyny as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in PGNY. Royal Bank of Canada boosted its position in shares of Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock worth $291,000 after buying an additional 10,340 shares during the period. Amundi raised its position in Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after buying an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock worth $5,630,000 after acquiring an additional 14,297 shares in the last quarter. Invesco Ltd. lifted its stake in Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company's stock worth $8,342,000 after acquiring an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC boosted its position in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company's stock worth $266,000 after acquiring an additional 780 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Progyny from a "hold (c+)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Zacks Research upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, July 8th. Barclays cut their target price on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 12th. Wall Street Zen lowered shares of Progyny from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 25th. Finally, Citizens Jmp boosted their price target on shares of Progyny from $31.00 to $33.00 and gave the company a "market outperform" rating in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Progyny currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.36.

Progyny Price Performance

PGNY opened at $27.35 on Friday. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The business has a 50-day moving average of $28.71 and a 200-day moving average of $24.01. The company has a market capitalization of $2.10 billion, a PE ratio of 29.73, a price-to-earnings-growth ratio of 1.89 and a beta of 0.99.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business had revenue of $350.51 million during the quarter, compared to analysts' expectations of $349.05 million. During the same quarter in the previous year, the business posted $0.19 EPS. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny announced that its board has approved a stock buyback program on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to purchase up to 10.3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's leadership believes its stock is undervalued.

Progyny Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company's services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.